Usefulness of Dofetilide for the Prevention of Atrial Tachyarrhythmias (Atrial Fibrillation or Flutter) After Coronary Artery Bypass Grafting

Postoperative atrial tachyarrhythmias (POAT) were a common complication in patients undergoing cardiac surgery and were associated with increased morbidity and hospital length of stay (LOS). Dofetilide is a class III antiarrhythmic that was never tested as a preventative therapy during the periopera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2008-06, Vol.101 (11), p.1574-1579
Hauptverfasser: Serafimovski, Nenad, MD, Burke, Peter, MD, Khawaja, Owais, MD, Sekulic, Milan, MD, Machado, Christian, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Postoperative atrial tachyarrhythmias (POAT) were a common complication in patients undergoing cardiac surgery and were associated with increased morbidity and hospital length of stay (LOS). Dofetilide is a class III antiarrhythmic that was never tested as a preventative therapy during the perioperative period. The aim of this study was to assess whether perioperative dofetilide is an effective and safe therapy for the prevention of POAT, with a decrease in LOS. A double-blind, randomized, placebo-controlled study of patients undergoing coronary artery bypass grafting with or without valve surgery was conducted. Patients were randomly assigned to receive either dofetilide or placebo. Medication was dosed and administered according to the manufacturer's guidelines. Daily review of cardiac monitoring was performed to assess for the occurrence of atrial fibrillation and atrial flutter. The primary outcome was defined as any atrial tachyarrhythmia lasting ≥5 minutes, whereas secondary outcomes included LOS and adverse events attributed to dofetilide. One hundred thirty-three patients were randomly assigned to dofetilide (n = 67) or placebo (n = 66). The incidence of POAT in the placebo arm was 24 (36%), and in the dofetilide arm, 12 (18%; absolute risk reduction 18%; p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2008.01.044